# OnCo record cachexia-appetite-pharmacotherapy (technology). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/technologies/cachexia-appetite-pharmacotherapy/>
  a schema:MedicalTherapy ;
  onco:kind "technology" ;
  schema:identifier "cachexia-appetite-pharmacotherapy" ;
  schema:name "Cachexia pharmacotherapy: GDF-15 blockade, anamorelin, olanzapine"@en ;
  schema:description "Cachexia pharmacotherapy covers three drug approaches to cancer wasting: ponsegromab, an antibody that blocks the appetite-suppressing hormone GDF-15 and is in phase 3; anamorelin, a ghrelin mimic approved only in Japan; and low-dose olanzapine, a generic tablet available everywhere that ASCO added to guidance in 2024. None has yet been shown to improve physical function."@en ;
  schema:url <https://onco.cc/technologies/cachexia-appetite-pharmacotherapy/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Cachexia> ;
  owl:sameAs <http://www.wikidata.org/entity/Q6003455> ;
  schema:citation <https://doi.org/10.1056/NEJMoa2409515>, <https://doi.org/10.1016/S1470-2045(15)00558-6>, <https://doi.org/10.1200/JCO.22.01997> ;
  onco:status "phase-3" ;
  onco:related <https://onco.cc/ideas/idea-bio2-anamorelin-access/>, <https://onco.cc/ideas/idea-bio2-low-dose-olanzapine-appetite/>, <https://onco.cc/ideas/idea-moon-cachexia-as-treatable-disease/>, <https://onco.cc/ideas/idea-bio2-cachexia-function-endpoint/> ;
  onco:cancers <https://onco.cc/cancers/pancreatic/>, <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/gastric/>, <https://onco.cc/cancers/colorectal/> ;
  onco:sections <https://onco.cc/fronts/nutrition-lifestyle/>, <https://onco.cc/fronts/supportive-care/> ;
  onco:technologies <https://onco.cc/technologies/cachexia-therapy/>, <https://onco.cc/technologies/oncology-nutrition/>, <https://onco.cc/technologies/resistance-training-cachexia/>, <https://onco.cc/technologies/antiemetic-therapy/> ;
  onco:drugs <https://onco.cc/drugs/megestrol-progestins/> ;
  onco:companies <https://onco.cc/companies/pfizer/> ;
  onco:institutions <https://onco.cc/institutions/tata-memorial/>, <https://onco.cc/institutions/ncc-japan/> ;
  onco:pathways <https://onco.cc/pathways/cachexia-biology/> ;
  onco:terms <https://onco.cc/terms/cachexia/>, <https://onco.cc/terms/sarcopenia/>, <https://onco.cc/terms/body-composition/> ;
  onco:trials <https://onco.cc/trials/romana-1-2/>, <https://onco.cc/trials/ponsegromab-phase-2/>, <https://onco.cc/trials/olanzapine-appetite-tmh/> ;
  onco:people <https://onco.cc/people/gupta-sudeep/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-cachexia-supportive/>, <https://onco.cc/bottlenecks/b-generic-repurposing/>, <https://onco.cc/bottlenecks/b-global-access/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-sandhya-j-clin-oncol/> .